Trigeminal neuralgia (TN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve. Carbamazepine (Tegretol, generics) is the only therapy formally approved for TN in the United States, but its use is limited by safety and tolerability concerns. Therefore, TN patients may be managed by a variety of off-label medications along their treatment journey, including oxcarbazepine (Supernus Pharmaceuticals’ Oxtellar XR, generics), gabapentin (Neurontin, generics), opioid analgesics, and even neuromuscular blocking agents (Allergan’s Botox). However, a substantial portion of TN patients are treatment-refractory, and better treatment options for these patients are needed.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis.
Key drugs covered: Carbamazepine / carbamazepine XR, oxcarbazepine, gabapentin, Lyrica, opioid analgesics, Botox, other antiepileptic drugs.
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.